Johnson & Johnson PE Ratio 2010-2023 | JNJ

Current and historical p/e ratio for Johnson & Johnson (JNJ) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Johnson & Johnson PE ratio as of February 23, 2024 is 15.52.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Johnson & Johnson PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-02-23 161.84 11.72
2023-12-31 155.56 $13.81 11.26
2023-09-30 153.36 $13.47 11.39
2023-06-30 161.82 $4.94 32.76
2023-03-31 150.39 $4.78 31.46
2022-12-31 170.20 $6.74 25.25
2022-09-30 156.39 $7.18 21.78
2022-06-30 168.80 $6.87 24.57
2022-03-31 167.48 $7.42 22.57
2021-12-31 160.62 $7.81 20.57
2021-09-30 150.63 $6.69 22.52
2021-06-30 152.74 $6.65 22.97
2021-03-31 151.44 $5.66 26.76
2020-12-31 144.12 $5.51 26.16
2020-09-30 135.38 $6.36 21.29
2020-06-30 127.04 $6.84 18.57
2020-03-31 117.63 $7.56 15.56
2019-12-31 130.01 $6.78 19.18
2019-09-30 114.52 $6.40 17.89
2019-06-30 123.28 $6.03 20.44
2019-03-31 122.89 $5.40 22.76
2018-12-31 112.71 $5.61 20.09
2018-09-30 119.91 $0.50 239.82
2018-06-30 104.60 $0.43 243.27
2018-03-31 109.66 $0.38 288.59
2017-12-31 118.81 $0.39 304.64
2017-09-30 109.88 $5.76 19.08
2017-06-30 111.10 $5.92 18.77
2017-03-31 103.92 $5.95 17.46
2016-12-31 95.50 $5.88 16.24
2016-09-30 97.25 $5.65 17.21
2016-06-30 99.20 $5.32 18.65
2016-03-31 87.86 $5.50 15.97
2015-12-31 82.81 $5.49 15.08
2015-09-30 74.71 $5.23 14.29
2015-06-30 77.39 $5.69 13.60
2015-03-31 79.31 $5.59 14.19
2014-12-31 81.86 $5.70 14.36
2014-09-30 82.91 $6.04 13.73
2014-06-30 80.83 $5.42 14.91
2014-03-31 75.37 $5.24 14.38
2013-12-31 69.77 $4.82 14.48
2013-09-30 65.58 $4.50 14.57
2013-06-30 64.47 $4.51 14.30
2013-03-31 60.76 $3.68 16.51
2012-12-31 51.83 $3.87 13.39
2012-09-30 50.51 $3.04 16.61
2012-06-30 49.07 $3.14 15.63
2012-03-31 47.45 $3.64 13.04
2011-12-31 46.77 $3.48 13.44
2011-09-30 45.00 $4.10 10.98
2011-06-30 46.59 $4.18 11.14
2011-03-31 41.14 $4.41 9.33
2010-12-31 42.56 $4.78 8.90
2010-09-30 42.27 $4.87 8.68
2010-06-30 39.91 $4.84 8.25
2010-03-31 43.66 $4.76 9.17
2009-12-31 42.81 $4.40 9.73
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $389.835B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.190B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Merck (MRK) United States $328.029B 86.30
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
AstraZeneca (AZN) United Kingdom $204.098B 18.08
Pfizer (PFE) United States $156.755B 15.17
Sanofi (SNY) $123.368B 11.11
Innoviva (INVA) United States $0.992B 8.95